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A B S T R A C TObjectives: This study evaluated the clinical and economic impacts of
clinical pharmacy education (CPE) on infection management among
patients with chronic kidney disease (CKD) stages 4 and 5 in Haji
Adam Malik Hospital, Indonesia. Methods: A quasi-experimental
economic evaluation comparing CPE impact on 6-month CKD mortal-
ity was conducted on the basis of payer perspective. The experimental
group (n ¼ 63) received care by health care providers who were given
CPE on drug-related problems and dose adjustment. The control
group (n ¼ 80) was based on the historical cohort of patients who
received care before the CPE. Measure of clinical outcome applied in
this study was number of lives saved/100 patients treated. Cost-
effectiveness ratios for CKD stages 4 and 5 patients without CPE and
with CPE and incremental cost-effectiveness ratios (ICERs) for CKD
stages 4 and 5 patients were analyzed. Results: Lives saved (%) in the
treatment of CKD without CPE: CKD stage 4, 78.57; CKD stage 5, 57.58.see front matter Copyright & 2013, International
r Inc.
.1016/j.vhri.2013.02.009
st: The authors have indicated that they have no
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ondence to: Azizah Nasution, Fakultas Farmasi, Un
esia.Lives saved (%) in the treatment of CKD with CPE: CKD stage 4, 88.89;
CKD stage 5, 65.45. Cost-effectiveness ratios for stage 4 with and
without CPEs were Rp3,348,733.27 and Rp3,519,931.009, respectively.
Cost-effectiveness ratios for stage 5 with and without CPEs were
Rp7,137,874.93 and Rp7,871,822.27, respectively. ICERs were
Rp2,045,341.22 for CKD stage 4 and Rp1,767,585.60 for CKD stage 5.
Conclusions: Treatment of CKD stages 4 and 5 with CPE was more
effective and cost-effective compared with treatment of CKD stages 4
and 5 without CPE. The ICERs indicated that extra costs were required
to increase life saved in both stages.
Keywords: chronic kidney disease, clinical pharmacy education, cost-
effectiveness, DRPs, infection.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Chronic kidney disease (CKD) is a worldwide public health
problem with increasing prevalence, high treatment cost, and
poor outcomes [1]. In Indonesia, up to now, there is no available
information regarding the accurate prevalence of CKD, but a
survey carried out in a few parts of the country found that 12.5%
of the population had CKD [2]. In the United States alone, the
prevalence of CKD increased from 10% in the period 1988 to 1994
to 13% in the period 1999 to 2004 [3]. In fact, epidemiologic
studies have demonstrated that the incidence of kidney diseases
is higher in the developing countries than in the developed world.
Global annual growth rate of CKD is 8% [4].
CKD is a costly disease to both patients and nations. In the
United States, the cost for hemodialysis per patient per year
was US $71,889 [5]. Barclay [6] found that almost a quarter of
the Medicare budget was spent for the treatment of CKD. In
Indonesia, the lowest cost for a single hemodialysis is about
Rp500,000 (US $53). This means that the annual cost required
to treat one patient is about Rp50,000,000 excluding other costssuch as those for drugs, routine blood tests, and other sup-
porting tests [7]. Most of the risk factors of CKD could be
prevented and cured if managed at early stages. The disease,
however, is usually underdiagnosed and undertreated, result-
ing in loss of opportunities for prevention and eventually
disability or death. A few studies on CKD in the United States
indicated that its treatment rate was only 14.1% [3]. The
diagnosis and management of CKD must always be performed
as early as possible to delay the progression of loss of kidney
function.
Patients with advanced stages of CKD usually have complex
comorbidities and complications. One of its common complica-
tions is infection, which is the second leading cause of death of
patients with CKD, especially those in stages 4 and 5 [7,8]. Its
inflammatory state can further lead to the development of
atherosclerosis and increased risk of cardiovascular disease.
Patients with CKD also usually experience neutrophil dysfunc-
tion because of complicated problems including malnutrition,
trace element deficiencies, iron overload, impaired glucose meta-
bolism, hyperparathyroidisms, and uremic retention solutes.Society for Pharmacoeconomics and Outcomes Research (ISPOR).
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lyzer reuse are also the possible sources of infection in patients
with CKD [9]. These complications expose them to a higher risk
for bacterial and viral infections. Epidemiological studies suggest
that the three most frequent infectious complications experi-
enced by patients with end-stage renal disease are urinary tract
infection, pneumonia, and sepsis [9]. It was found that the
mortality rate of patients treated with hemodialysis was about
100- to 300-fold than that of patients without hemodialysis
[10]. As such, numerous medications are always required to
treat advanced stages of CKD and its comorbidities and com-
plications. These can further result in drug-related problems
(DRPs), ineffective treatment, and inefficient resource utiliza-
tion [11].
Two of the frequently occurring DRPs are irrational dosing
(too little or too much of the drug provided to the patients) and
drug interaction (comprising drug–drug, drug–food, and
drug–laboratory interactions) [12]. These DRPs can worsen
outcomes of patients with CKD if not managed according to
established guidelines. For example, incorrect dose of many
drugs such as antibiotics provided to patients with CKD can
accumulate in the body, resulting in toxic effects to organs
including kidneys. The progress of the kidney damage will also
be accelerated [13,14]. In addition, there is an increased chance
of drug interaction due to multiple drug therapy, which could
lead to inefficient and ineffective treatment of the disease. An
example is concomitant administration of enzyme inhibitors
such as ranitidine sometimes prescribed to eliminate nausea
and vomiting caused by cephalosporines, which will elevate
the drugs’ level in the body, exacerbate the cephalosporines’
nephrotoxicity, and accelerate kidney damage. The ultimate
negative outcome is death [15].
A great deal of attention has to be paid to the improve-
ment of CKD outcomes and its treatment cost. Ernst and Grizzle
[16] found that every US $1 spent on medication required
US $1.77 on DRPs. Thus, to improve outcomes and minimize
costs, a concrete approach needs to be taken to prevent and
resolve DRPs.
The participation of pharmacists trained in clinical skills
with other health care providers is crucial in optimizing drug
therapy [17–19]. Such clinical skills can be imparted through
a structured CPE program. This study was conducted to eval-
uate the impacts of clinical pharmacy education (CPE) on out-
come and costs in the management of infection among patients
with CKD stages 4 and 5 in Haji Adam Malik (HAM) Hospital,
Indonesia.Methods
A quasi-experimental economic evaluation comparing CPE
impact on 6-month CKD mortality was conducted on the basis
of Jaminan Kesehatan Masyarakat (JAMKESMAS) or public health
insurance perspective. JAMKESMAS is a social insurance funded
by the Indonesian government covering 76.4 million people
(one-third of the Indonesian population). The insurance aims
to protect the poor and near-poor population from the cata-
strophic payment due to sickness [20]. The experimental group (n
¼ 63) received care by health care providers who were given CPE
on DRPs and dose adjustment. The control group (n ¼ 80) was
based on the historical cohort of patients who received care
before the CPE.
As the perspective of the study was from the payer’s point of
view, only direct costs consumed by the control and experimental
groups of patients with CKD were included in the economic
analysis.Clinical Pharmacy Education
Prior to the CPE, 3-month data were collected from JAMKESMAS
inpatients database by using a predefined data collection form.
The data were analyzed descriptively to identify antibiotic usage-
associated problems and other related drugs administered to the
patients. The results of this analysis were used to prepare
materials for the CPE. In addition, the CPE highlighted common
issues including dose adjustment according to the level of kidney
function, frequently administered antibiotics for the patients,
and frequently occurring drug-drug interactions as identified
from the patients’ medical charts. The CPE was conducted by a
clinical pharmacist through a half-day formal seminar (officially
scheduled and organized by the head of installation of research
and development HAM Hospital) and two informal (unofficial)
one-to-one discussion sessions regarding issues raised by the
health care providers. The participants of the CPE were pharma-
cists who work at the installation of pharmacy, physicians and
nurses who serve in the installation of nephrology, and other
related employees selected by the head of the installation of
research and development. The printed materials of the CPE were
also distributed to the participants.
Data Collection
Data were extracted from 6-month JAMKESMAS database of
inpatients with CKD stages 4 and 5 receiving treatment of anti-
biotics starting from admission until discharge for the middle
of September 2009 to the middle of March 2010 as control group
(n ¼ 80) and middle of March to middle of September 2010 as
experimental group (n ¼ 63) by using a predetermined data
collection form. Inclusion criteria were infectious patients with
glomerular filtration rate of less than 15 ml/min/1.74m2 surface
area. Patients younger than 18 years or with cancer and human
immunodeficiency virus were excluded from this study [21,22].
The data recorded on the data collection form included date of
admission, medical record number, age, sex, patient conditions
at admission (stage of CKD), patient condition at the end of
treatment (death or survive), number and unit cost of laboratory
tests, and antibiotics and other drugs administered.
Data Analysis
Characteristics of the patients
The characteristics of patients with CKD were grouped and
analyzed according to age, sex, and severity of the disease.
Grouping of the patients with CKD on the basis of severity was
performed by calculating the glomerular filtration rate applying
the Modification of Diet in Renal Disease study equation [23].
Their mean values were statistically analyzed at the 95% con-
fidence level (Po 0.05 is considered significant).
Cost-effectiveness analysis
Effectiveness. It has been known that CKD is a life-threatening
disease [24]. Thus, final outcome is the appropriate measure-
ment for this disease. In this study, it was measured as number
of lives saved per 100 patients with CKD (percentage of
patients who survived over those who were treated) in the
control and experimental groups [25]. Before performing cost-
effectiveness analysis (CEA), a formal testing for the effective-
ness for CPE in terms of mortality was conducted and it was
found that there was no statistically significant difference in
terms of mortality reduction between groups with and without
CPEs (P ¼ 0.342).
Health care resources consumed. Components of the health care
resources accounted in this study included drugs, floor stock,
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treatment administration, hemodialysis service, physician vis-
its/consultations, chemicals, emergency service, radiology serv-
ice, serology service, card and ticket, blood flask, eye polyclinic,
surgery, bacteriology test, and clinical pharmacy education.
Other health care costs including hotel, cleaning, catering, electri-
city, water, and building depreciation were considered to be
accounted in the hospital accommodation charge.
Steps in performing CEA. Few assumptions were made in this
study: Infecting pathogens were the same among each group of
patients with CKD. Patients did not suffer from other concom-
itants diseases because they can modify drugs provided and
affect outcomes; only serious adverse events increased the cost
of treatment, and each adverse event prolonged the hospital stay;
there was no impact of antibiotic resistance on costs.
Direct medical costs were analyzed by multiplying the number
of doses/test/service/unit given with cost per dose/test/service/
unit. Direct nonmedical costs were obtained by multiplying the
hospital length of stay with accommodation charge per day. In
this study, the cost-effectiveness of the group with and without
CPEs was compared on the basis of costs and effectiveness of
treating 100 patients.
Samples with and without CPEs were stratified according to the
stage of the disease (a). Percentage of patients with CKD stages 4
and 5 with and without CPEs treated (outcome/100 patients)
were calculated (b). Direct costs consumed for the treatment of
individual patient of CKD stages 4 and 5 with and without CPEs
were calculated (c). Cumulative direct costs consumed for the
treatment of exiting number of CKD stages 4 and 5 patients
(
P
Ci) with and without CPEs were calculated (d). Each of the
values obtained in point d) was converted into cost consumed to
treat 100 patients (cost/100 patients) (e). Cost-effectiveness ratio
of each of the subgroup treatments was calculated by dividing
the value obtained in point e) by the value obtained in point b).
Incremental cost-effectiveness ratios (ICERs) in the manage-
ment of CKD stages 4 and 5 were analyzed by calculating
(Costwith CPE – Costwithout CPE)/(Outcomewith CPE – Outcomewithout
CPE) [26].
Sensitivity analysis. In this study, one-way sensitivity analysis
was undertaken to improve the quality and usefulness of
the CEA. Here, drug costs were increased to 5%, 10%, and
15%. The new costs, cost-effectiveness ratios, and ICER were
recalculated [25].
All calculations and result plotting were performed by using
Microsoft Excel 2007 (Microsoft Corp, Redmond, WA) and SPSS for
Windows (version 17; SPSS Inc, Chicago, IL).Table 1 – Characteristics of the control and experimenta
Demographic variable Control group (n
Age (y), mean  SD 47.06  13.8
Within group: applying one-sample
t test; tested value ¼ 0.5
Proportion SD
Sex:
Male 53 (0.66) 0.48
Female 27 (0.34)
Severity:
Stage 4 14 (0.17) 0.38
Stage 5 66 (0.83)Results
Characteristics of the patients
Characteristics of the studied populations are shown in Table 1.
There were 80 patients included in the control group. Of these, 66%
were men and 34% were women. The experimental group consisted
of 63 patients. Sixty-three percent were men, and 37% werewomen.
Ages of the control and experimental groups were 47.06  13.80
years and 49.44  13.08 years, respectively. As shown in Table 1,
there was more admission of patients with CKD stage 5 in both
groups compared with those with CKD stage 4. By age, there was no
statistically significant difference between the experimental and
control groups (P ¼ 0.299). By gender, in the group without CPE, the
disease was more prevalent in men than in women (P ¼ 0.003). A
similar result was obtained in that the disease was also more
prevalent in men than in women in the group with CPE (P ¼ 0.031).
In the group without CPE, CKD stage 5 was more prevalent than
CKD stage 4, (Po 0.001). Similarly, CKD stage 5 was also more
prevalent than CKD stage 4 in the group with CPE (Po 0.001).Cost-Effectiveness Analysis
The resources used to treat patients with CKD according to group
(non-CPE and CPE) and stage (stages 4 and 5) are presented in Table 2.
The direct cost consumed to treat 100 patients with CKD stage 4
without CPE was Rp276,560,978.57 with outcome or lives saved of
78.57%, whereas the direct cost consumed to treat 100 patients with
CKD stage 4 with CPE was Rp297,668,900.00 with lives saved of
88.89%. Hence, cost-effectiveness ratios in the management of
patients with CKD stage 4 with and without CPEs were
Rp3,348,733.27 and Rp 3,519,931.00, respectively. In other words, costs
per life saved were Rp3,348,733.27 and Rp3,519,931.00 for patients
with CKD stage 4 with and without CPEs, respectively. Based on the
analysis of ICER, however, to increase life saved from 78.57% to
88.89%, Rp2,045,341,22 of extra cost per patient was required.
Similar results were also obtained for the treatment of
patients with CKD stage 5 with and without CPEs. The cost
consumed by 100 patients with CKD stage 5 without CPE was
Rp453,263,015.52 with outcome or lives saved of 57.58%, whereas
the cost consumed to treat 100 patients with CKD stage 5 with
CPE was Rp467,173,914.18 with lives saved of 65.45%. Thus, cost-
effectiveness ratios of CKD stage 5 patients with and without
CPEs were Rp7,137,874.93 and Rp7,871,882.87, respectively. Anal-
ysis of ICER for non-CPE and CPEs groups of CKD stage 5
indicated that Rp1,767,585.60 of extra cost per patient was
required to increase live saved from 57.58% to 65.45%.l groups.
¼ 80) Experimental group (n ¼ 63) P
0 49.44  13.08 0.299
P Proportion SD P
0.003 40 0.48 0.031
(0.63)
o0.001 23 0.37 o0.00
(0.37) 1
8 (0.16)
55 (0.84)
Table 2 – Cost-effectiveness analysis in group with and without CPEs.
Description Without CPE With CPE
Stage 4 (n ¼ 14) Stage 5 (n ¼ 66) Stage 4 (n ¼ 8) Stage 5 (n ¼ 55)
Direct medical cost Rp34,938,537.00 Rp276,918,614.00 Rp21,653,012.00 Rp243,850,649.80
Direct nonmedical cost (hotel) Rp3,780,000.00 Rp22,235,000.00 Rp2,160,500.00 Rp13,095,003.00
Total Rp38,718,537.00 Rp299,153,614.00 Rp23,813,512.00 Rp256,945,652.80
Cost to treat 100 patients Rp276,560,978.57 (x1) Rp453,263,015.52 (x2) Rp297,668,900.00 (x3) Rp467,173,914.18 (x4)
Outcome (hypothetical lives saved per
100 patients treated) (y)
78.57 (y1) 57.58 (y2) 88.89 (y3) 65.45 (y4)
CE ratio ¼ x/y Rp3,519,931.00/life
saved
Rp7,871,882.87/life
saved
Rp3,348,733.27/life
saved
Rp7,137,874.93/life
saved
ICER
CKD stage 4 (Cost x3 – Cost x1)/(Outcome y3  Outcome y1) ¼ 21,107,921.43/10.32 ¼ 2,045,341.22
CKD stage 5 (Cost x4 – Cost x2)/(Outcome y4  Outcome y2) ¼ 13,910,898.66 /7.87 ¼ 1,767,585.60
CKD, chronic kidney disease; CPE, clinical pharmacy education; ICER, incremental cost-effectiveness ratio.
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Result of the sensitivity analysis is presented in Table 3. This
analysis shows that even though the acquisition costs were
increased by 15%, the overall conclusions did not change. In
other words, it could be concluded that the results of the CEA
were robust to uncertainty on the drug cost.Discussion
Up to now, there are still limited studies undertaken on CKD in
Indonesia. This present study indicated that CPE improved
effectiveness (lives saved) and decreased costs for the treatment
of infection in patients with CKD stages 4 and 5 as previously
mentioned. These results may have been due to a decrease in the
number of drugs administered to the patients with CKD, DRPs,
and their hospital length of stay. Therefore, this finding implied
that CPE had positive impacts on the management of CKD.
As indicated by analysis of ICER, extra costs were needed to
improve outcome in the treatment of both stages. This analysis is
essential to undertake in any pharmacoeconomic study because
it can be used as a guidance to decide whether such amount ofTable 3 – Result of the sensitivity analysis.
Description With
Stage 4 (n ¼ 14)
Direct cost to treat 100 patients (x) at increased:
5% of acquisition cost Rp276,461,028.50
10% of acquisition cost Rp348,930,950.30
15% of acquisition cost Rp493,860,119.80
Outcome (lives saved per 100 patients treated) (y) 78.57 (Y1)
CE ratio (x/y) in Rp/life saved at increased:
5% of acquisition cost 3,518,658.00
10% of acquisition cost 4,441,020.00
15% of acquisition cost 6,285,606.00
ICER at increased: S
5% of acquisition cost Do
10% of acquisition cost Do
15% of acquisition cost Do
CPE, clinical pharmacy education; ICER, incremental cost-effectiveness rmoney is an acceptable or reasonable amount to pay by the
policymaker [27]. In this case, to decide whether to include CPE
into the management of CKD depends on, to large extent, budget
limitation provided by JAMKESMAS as the payer. Extrapolated
ICERs for the management of CKD stages 4 and 5 patients would
be equal to about US $216.81 and 187.36, respectively. These
values are less than the estimated Indonesian gross domestic
product per capita for year 2010, US $4500 [28,29]. Therefore,
based on the World Health Organization-choice threshold, the
ICERs are cost-effective.
Sensitivity analysis demonstrated that increasing acquisition
costs did not affect the result of CEA. In other words, it could be
concluded that the results of this analysis are robust to uncer-
tainty or the management of patients with CKD with CPE is more
cost-effective compared with that of those without CPE.
This finding supports other studies undertaken by research
groups in few hospitals in several countries, but focusing on
different outcomes. A literature review undertaken on 14
randomized controlled studies with different settings indicated
that clinical pharmacy intervention reduced DRPs to various
levels [30]. A review conducted by Salgado et al. [31] summarized
that pharmacists’ interventions in the management of CKD have
shown positive impacts on the treatment outcomes. With regardout CPE With CPE
Stage 5 (n ¼ 66) Stage 4 (n ¼ 8) Stage 5 (n ¼ 55)
Rp459,742,172.70 Rp301,232,650.60 Rp469,900,342.00
Rp464,770,852.00 Rp304,796,401.30 Rp472,622,099.20
Rp469,799,531.40 Rp308,360,151.90 Rp475,343,855.90
57.58 (Y2) 88.89 (Y3) 65.45 (Y4)
7,984,407.00 3,388,824.96 7,179,531.59
8,071,741.00 3,428,916.65 7,221,116.87
8,159,074.00 3,469,008.35 7,262,702.15
tage 4 Stage 5
minant Dominant
minant Dominant
minant Dominant
atio.
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on the impact of renal drug dosing service on dose adjustment in
hospitalized patients with CKD. The finding indicated that cost
avoidance amounted to US $2250 during a period of 4 months in
2007 [32]. An anemia educational program performed by phar-
macists for patients with CKD had significant effects on the
patients’ energy, daily activities, and general well-being [33].
Another pharmaceutical care intervention performed by Wang
et al. [34] in renal transplant clinics made 55 recommendations,
of which 81.8% were classified as clinically significant. A random-
ized controlled study conducted on 104 patients with end-stage
renal disease found that drug use, rate of hospitalization, and
cost were lower in the group with pharmaceutical care compared
with those receiving standard care [35]. A conclusion could be
drawn that CPE has positive impacts on CKD management.
This study was limited by the relatively small sample size and
CPE sessions. A number of factors including bacterial resistance
to antibiotics, variability of the infecting bacteria, complications,
and comorbidities of the disease were not accounted and
assumed to be similar for all patients in this study. These factors
could affect the patients’ mortality and hospitalization; hence,
these need to be properly addressed in the future.Conclusions
CPE improved effectiveness and efficiency of CKD management.
Thus, involvement of clinical pharmacists in the team of multi-
disciplinary health care providers is important to obtain optimal
services. This finding should be considered by the policymakers
in the HAM Hospital and other hospitals in general.
Source of financial support: There was no funding provided to
this study.
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